Modelling accessibility of adult neurology care in Australia, 2020–2034

Steve Simpson-Yap 1,2,3, Federico Frascoli,4 Lucinda Harrison,1 Charles Malpas1,5 James Burrell6, Nicholas Child7, Lauren P Giles8, Christian Lueck9, Merrilee Needham10, Benjamin Tsang11, Tomas Kalincik1,5 On behalf of the Australian & New Zealand Association of Neurologists Workforce Committee

ABSTRACT
Introduction In 2015/2016, annual national expenditure on neurological conditions exceeded $A3 billion. However, a comprehensive study of the Australian neurological workforce and supply/demand dynamics has not previously been undertaken.

Methods Current neurological workforce was defined using neurologist survey and other sources. Workforce supply modelling used ordinary differential equations to simulate neurologist influx and attrition. Demand for neurology care was estimated by reference to literature regarding incidence and prevalence of selected conditions. Differences in supply versus demand for neurological workforce were calculated. Potential interventions to increase workforce were simulated and effects on supply versus demand estimated.

Results Modelling of the workforce from 2020 to 2034 predicted an increase in neurologist number from 620 to 896. We estimated a 2034 capacity of 638,024 Initial and 1,269,112 Review encounters annually, and deficits against demand estimated as 197,137 and 881,755, respectively. These deficits were proportionately greater in regional Australia, which has 31% of Australia’s population (Australian Bureau of Statistics) but is served by only 4.1% of its neurologists as determined by our 2020 survey of neurological members. Nationally, simulated additions to the neurological workforce had some effect on the review encounter supply deficit (37.4%), but in Regional Australia, this impact was only 17.2%.

Interpretation Modelling of the neurologist workforce in Australia for 2020–2034 demonstrates a significant shortfall of supply relative to current and projected demand. Interventions to increase neurologist workforce may attenuate this shortfall but will not eliminate it. Thus, additional interventions are needed, including improved efficiency and additional use of support staff.

WHAT IS ALREADY KNOWN ON THIS TOPIC
⇒ There is a shortfall in the capacity of the neurological care support structure to meet patient demand. This is anecdotally known in Australia but has not been quantitatively assessed previously.

WHAT THIS STUDY ADDS
⇒ This is the first study of the neurology workforce in Australia and its ability to meet estimated patient demand in 2020 and 2034, as well as under certain simulated scenarios.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY
⇒ We show a significant insufficiency in the neurology care supply in Australia, this even worse in regional Australia. We show that merely adding additional neurologists, even were this possible with existing resources, is not projected to meet the capacity shortfall. Thus, additional methods, including improved efficiency for referral and care pathways, expansion of the neurology support workforce, and improvements in the ability to general practitioners manage more basic neurological issues, are needed to meet the workforce capacity shortfall.

deficiency in the capacity of its neurological workforce to meet demand. To address this situation, it would be helpful to model the current position and assess the impact of potential future interventions. Such modelling has been undertaken in other healthcare settings but efforts to model the supply and demand of neurology workforce worldwide are few and varied. Kurtzke first quantified patient demand for neurological care in the USA in 1981. Based on prevalence and incidence rate estimates of neurological conditions, prevalent need among 3.6% of the population for neurological care each year was estimated, alongside 0.6% of the population with an incident condition requiring neurological assessment. In Greater London in 1995–1996, MacDonald et al estimated new
neurological disorders in 0.6% of the population and a lifetime prevalence in 6% of the population. Building on a previous US study by Bradley, Dall et al modelled neurology demand in the USA over 2012–2025, based on modelling of patient numbers for selected conditions needing neurological care, finding persistent supply deficits. Simulated interventions, including increased neurologist workforce and delayed retirement, were unable to eliminate these shortfalls. Applying the prevalence and incidence statistics from the Kurtzke and MacDonald studies, Ranta et al modelled the neurology workforce in New Zealand over 2014–2016, finding deficits in supply in all scenarios. Simulated interventions adding neurologists, increasing efficiency and adding neurological nursing specialists reduced the deficit, but none realised sustained elimination of the supply deficit.

There has never been a study of the neurological workforce in Australia. The Australia and New Zealand Association of Neurologists (ANZAN) established a Workforce Committee to estimate the current neurology workforce and its capacity to meet demand in Australia. Accordingly, we undertook a survey of ANZAN neurologist members and acquired other necessary data to estimate the neurologist workforce supply in Australia, nationally and in regional Australia, in 2020 and projected to 2034. We also simulated interventions to introduce additional neurologists to the workforce and modelled resultant impacts on the supply-demand dynamics.

**METHODS**

**Estimation of neurology care demand**

After updating the list of conditions requiring neurology care, updated prevalence and incidence estimates were derived from the literature. In addition, the fractions of patients with each condition, and typical consult frequencies for each condition, were used to estimate initial and review patient demand in 2020 and 2034 (online supplemental tables 1–2). Typical consultation durations for initial and review encounters were estimated for each condition, and then these were used to estimate the durational load. The frequencies and durations of clinic attendance were based on internal expert opinion by the ANZAN Workforce Committee. Supply durations for initial and review encounters were estimated as the mean values expected for the current epidemiology of neurological conditions.

To allow comparison with previous reports, we also estimated demand based on the Kurtzke-MacDonald statistics.

**Model of Australian neurology workforce**

The total number of adult neurology consultants was derived from Royal Australian College of Physicians (RACP) Internal Membership Reports for 2019 and 2020. In order to undertake specialised neurology training to practice neurology in Australia, registration as a trainee with the RACP is required, with successful trainees are then invited to become Fellows of the RACP. Therefore, estimates based on the numbers of RACP fellows is comprehensive of neurologists in Australia. We estimated the numbers of active neurology RACP fellows working in Australia in adult neurology over 2012–2020 (online supplemental table 3). Cohort characteristics from the 2020 ANZAN survey are shown in online supplemental tables 5 and 6. We applied the proportions from the 2020 ANZAN survey of neurologists working in the last 12 months who were also working in the previous 5 years but not earlier than this (60.3%), and then those working earlier than 5 years’ previously (39.7%), the former defining early-career and the latter mid/late-career neurologists. Adding to these, we used internal data provided by ANZAN for the number of active advanced trainees over 2017–2020. These figures were used to estimate numbers of early-career and mid-career/late-career neurologists and trainees.

According to the Australian Bureau of Statistics, the population in regional Australia is 31.0% of the national population; however, the 2020 ANZAN survey found only 4.1% of neurologists reported primarily working in regional Australia. Accordingly, we applied this 4.1% proportion to estimate the number of neurologists in regional Australia in 2017–2020, this also used for estimates in 2034.

**Forecasting neurology workforce to 2034**

The modelling of neurologist career progression in Australia used the numbers of basic physician trainees, advanced neurology trainees, early-career neurologist consultants, mid-career/late-career neurology consultants and semiretired (figure 1, online supplemental table 4). Entering the system are medical students completing basic physician training (α) and practitioners immigrating to Australia (μ). Exiting the system are practitioners leaving neurology, retiring or emigrating (γ). The modelled transitions between states include the transition from basic physician to advanced neurology trainee (λ₀), from advanced neurology trainee to early-career neurologist (λ₁) and from early-career to mid-career/late-career neurologist (λ₂). Mid-career/late-career neurologists were allowed to transition to semiretired (s₁) and thence to retired (s₂).

![Figure 1](http://neurologyopen.bmj.com/) Neurologist career progression model used for estimating and projecting neurologist numbers.
A set of ordinary differential equations (ODEs) (figure 2) was used to estimate projected numbers of neurologists in national and regional Australia, using appropriate parameters and initial conditions. ODE analyses were conducted using Wolfram Mathematica for Windows V.12.1.1 (Wolfram Research, Champaign, USA). For simplicity, the set of ODEs considers a fixed, annual influx of neurologists from the basic physician trainees, captured by the parameter, $\lambda_m$. Also, given that the difference between the rates $s_1$ and $s_2$ is minimal, please note that we put $s_1=s_2=s$.

Estimating supply of outpatient neurology care
We estimated the number of clinic encounters by multiplying the number of active neurology practitioners working in adult neurology in Australia by the numbers of initial and review encounters per week and the mean number of weeks typically worked per year. We then estimated the durational supply by multiplying patient numbers by estimated typical consult duration, these increments defined as the weighted average of durations for each neurological condition from our updated review (online supplemental tables 1–2). This thus estimated durations of 46.9 min for initial and 23.6 min for review encounters.

Estimation of supply versus demand of neurology care
We estimated the gap between the supply of neurology outpatient care and clinical demand in two fashions. First, we subtracted the number of new and review encounters from the number of available encounters. Second, we preferentially allocated capacity to the 10% of initial encounters (representing urgent referrals), with the remaining capacity allocated to review encounters and then to remaining initial encounters. We also evaluated alternative proportions (20%, 30%, 40% and 50%) of initial encounters to be reviewed urgently (online supplemental table 11).

Simulated interventions
In addition to natural growth over 2022–2031, we evaluated adding an extra 5, 10 or 20 new neurologists per year nationally, and 2, 5 or 10 new neurologists per year in regional Australia.

RESULTS
Model of Australian neurology workforce
Based on the evolution of the Australian neurology workforce over the previous years, we estimated that there were 620 neurologists practising in adult neurology in Australia in 2020, this forecasted to increase to 896 in 2034 (figure 3). We then simulated interventions, adding an extra 5, 10 or 20 new neurologists per year over...
2022–2031, resulting in 935, 973 and 1051 neurologists, respectively, for Australia in 2034.

Regionally, there were 25 neurologists in 2020, forecasted to increase to 33 in 2034 (figure 4). On simulation of adding an extra 2, 5 and 10 new neurologists each year over 2022–2031, the numbers of neurologists in regional Australia in 2034 were estimated to be 46, 65 and 97, respectively.

Prevalence and incidence-based estimates of demand
In 2020, there was capacity for 441,490 initial encounters and 878,180 review encounters. This capacity was forecasted to increase to 638,024 initial and 1,269,112 review encounters in 2034.

In 2020, the capacity for initial encounters exceeded the demand by 269,591 initial encounters, with a large deficit of 1,322,516 review encounters, both persisting at 2034 (table 1). A more realistic allocation of neurological capacity, first allocated to 10% of the initial encounters with the remainder of capacity used to meet the need for review encounters, there were deficits of 154,889 initial encounters in 2020 and 197,137 in 2034, and of 898,236 review encounters in 2020 and 881,755 in 2034. Simulating the introduction of 50–200 new neurologists over 2022–2031, deficits in review encounter capacity were reduced by 37.4% to 551,838 (online supplemental table 7, figure 5).

In regional Australia in 2020, there was capacity for 17,802 initial and 35,411 review encounters. This capacity was forecasted to increase to 23,499 initial and 46,742 review encounters in 2034. In 2020, the deficits in supply in regional Australia reached 35,549 for initial encounters and 646,805 for review encounters, increasing in 2034 to 44,404 and 811,024, respectively. Applying preferential allocation of capacity to review encounters, initial and review encounter deficits were 48,016 and 634,357 in 2020 and 61,113 and 794,316 in 2034, respectively. Simulated addition of up to 100 extra neurologists to regional Australia over 2022–2031, the deficit in review encounters was reduced by 17.2% to 658,092 (online supplemental table 9, figure 6).

Estimation of durational supply and demand for neurological care
Taking into account consult durations for initial (46.9 min) and review (23.6 min) encounters, deficits were reduced but not eliminated. Applying the preferential allocation of capacity to review encounters, there was a deficit in capacity for initial encounters of 121,003 in 2020 and 154,008 in 2034; review capacity was short by 207,468 in 2020 and 111,667 in 2034 (table 2). By simulated introduction of 50–200 new neurologists over 2022–2031, the deficit in review encounters could be eliminated only by the maximum simulated addition (online supplemental table 8).

In regional Australia, deficits persisted in 2020 and 2034 for both initial (37,511 and 47,743) and review (249,544 and 305,768) encounters. On simulating the introduction of up to 20–100 additional neurologists to regional Australia over 2022–2031, the deficit in review encounters could be reduced by up to 23.2% to 234,868 (online supplemental table 10).

Kurtzke–MacDonald estimates of demand
The numbers of people estimated to need specialty neurological care were underestimated when based on the estimates by Kurtzke10 and MacDonald et al.11 However, we include them here for comparison with previous studies.

![Figure 4](https://example.com/figure4.png)

**Figure 4** Projected numbers of neurologists in regional Australia, 2020–2034, including with simulated addition over 2022–2031 of an extra 2, 5 and 10 neurologists per year.
According to the Kurtzke-McDonald estimations, patient capacity for initial encounters would exceed demand by 277,395 in 2020 and 441,729 in 2034, while for review encounters there would be a deficit of 105,893 in 2020 but a surplus of 91,340 in 2034. In regional Australia, the capacity for initial encounters would fall short of demand by 33,070 in 2020 and 37,353 in 2034, while for review encounters there would be a deficit of 33,070 in 2020 and 37,353 in 2034.

### Table 1  Neurology encounter supply and demand estimation, national and regional, 2020–2034, updated incidence and prevalence-based demand estimates

<table>
<thead>
<tr>
<th></th>
<th>Australia</th>
<th></th>
<th>Regional Australia</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2020</td>
<td>2034</td>
<td>2020</td>
<td>2034</td>
</tr>
<tr>
<td>Supply of neurological care</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurologists</td>
<td>620</td>
<td>896</td>
<td>25</td>
<td>33</td>
</tr>
<tr>
<td>Weeks/year</td>
<td>43</td>
<td>43</td>
<td>43</td>
<td>43</td>
</tr>
<tr>
<td>Initial encounters per week (2.75 per clinic)*</td>
<td>16.56</td>
<td>16.56</td>
<td>16.56</td>
<td>16.56</td>
</tr>
<tr>
<td>Review encounters per week (5.49 per clinic)*</td>
<td>32.94</td>
<td>32.94</td>
<td>32.94</td>
<td>32.94</td>
</tr>
<tr>
<td>Initial encounters/year†</td>
<td>441,489.60</td>
<td>638,023.68</td>
<td>17,802.00</td>
<td>23,498.64</td>
</tr>
<tr>
<td>Review encounters/year‡</td>
<td>878,180.40</td>
<td>1,269,112.32</td>
<td>35,410.50</td>
<td>46,741.86</td>
</tr>
<tr>
<td>Demand for neurological care§</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial encounters/year</td>
<td>172,099.08</td>
<td>219,041.47</td>
<td>53,350.71</td>
<td>67,902.86</td>
</tr>
<tr>
<td>Review encounters/year</td>
<td>2,200,696.20</td>
<td>2,766,987.22</td>
<td>682,215.82</td>
<td>857,766.04</td>
</tr>
<tr>
<td>Difference between supply and demand of neurological care§</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial encounters/year</td>
<td>Demand fully met</td>
<td>Demand fully met</td>
<td>−35,548.71</td>
<td>−44,404.22</td>
</tr>
<tr>
<td>Review encounters/year</td>
<td>−1,322,515.80</td>
<td>−1,497,874.90</td>
<td>−646,805.32</td>
<td>−811,024.18</td>
</tr>
</tbody>
</table>

 Supply versus demand based on Australia national disease-specific patient counts§, 10% Initial allocation first, then remaining capacity to review

<table>
<thead>
<tr>
<th></th>
<th>2020</th>
<th>2034</th>
<th>2020</th>
<th>2034</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial encounters/year</td>
<td>−154,889.17</td>
<td>−197,137.32</td>
<td>−48,015.64</td>
<td>−61,112.57</td>
</tr>
<tr>
<td>Review encounters/year</td>
<td>−898,236.11</td>
<td>−881,755.37</td>
<td>−634,356.88</td>
<td>−794,315.82</td>
</tr>
</tbody>
</table>

*Initial and review encounter numbers derived from 2020 ANZAN Member Survey.
†Capacity for initial encounters estimated as: number of neurologists×FTE fraction×weeks/year×# initial patients per week.
‡Capacity for review encounters estimated as: number of neurologists×FTE fraction×weeks/year×# review patients per week.
§Estimated initial and review encounter load based on disease-specific encounter counts as in online supplemental table 1. ANZAN, Australia and New Zealand Association of Neurologists; FTE, Full time equivalent.
Table 2  Estimation of durational supply and demand for neurological care, national and regional, 2020–2034, updated incidence and prevalence-based demand estimates

<table>
<thead>
<tr>
<th></th>
<th>Australia</th>
<th>Regional Australia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2020</td>
<td>2034</td>
</tr>
<tr>
<td><strong>Supply of neurological care</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurologists</td>
<td>620</td>
<td>896</td>
</tr>
<tr>
<td>Weeks/year</td>
<td>43</td>
<td>43</td>
</tr>
<tr>
<td>Initial encounters per week (2.75 per clinic)*</td>
<td>16.56</td>
<td>16.56</td>
</tr>
<tr>
<td>Review encounters per week (5.49 per clinic)*</td>
<td>32.94</td>
<td>32.94</td>
</tr>
<tr>
<td>Initial encounters/year†</td>
<td>441489.60</td>
<td>638023.68</td>
</tr>
<tr>
<td>Review encounters/year§</td>
<td>878180.40</td>
<td>1269112.32</td>
</tr>
<tr>
<td><strong>Durational supply of neurological care, hours (60 min per new, 30 min per review)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial encounters/year†</td>
<td>344361.89</td>
<td>497698.47</td>
</tr>
<tr>
<td>Review encounters/year§</td>
<td>342490.36</td>
<td>494953.80</td>
</tr>
<tr>
<td><strong>Durational demand for neurological care‡</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial encounters/year</td>
<td>134447.29</td>
<td>171878.64</td>
</tr>
<tr>
<td>Review encounters/year</td>
<td>880875.74</td>
<td>1087167.43</td>
</tr>
<tr>
<td><strong>Supply vs 1-year average durational demand based on Australia national disease-specific patient counts‡</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial encounters/year</td>
<td>Demand fully met</td>
<td>Demand fully met</td>
</tr>
<tr>
<td>Review encounters/year</td>
<td>−538385.39</td>
<td>−592213.62</td>
</tr>
<tr>
<td><strong>Supply vs 1-year average durational demand based on Australia national disease-specific patient counts‡, 10% Initial allocation first, then remaining capacity to review</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial encounters/year</td>
<td>−121002.56</td>
<td>−154007.67</td>
</tr>
<tr>
<td>Review encounters/year</td>
<td>−207468.23</td>
<td>−111667.12</td>
</tr>
</tbody>
</table>

*Initial and review encounter numbers derived from 2020 ANZAN Member Survey.
†Capacity for initial encounters estimated as: number of neurologists×FTE fraction×weeks/year×# initial encounters per week.
‡Estimated initial and review encounter load based on disease-specific encounter counts as in online supplemental table 1.
§Capacity for review encounters estimated as: number of neurologists×FTE fraction×weeks/year×# review encounters per week.
ANZAN, Australia and New Zealand Association of Neurologists; FTE, Full time equivalent.

Figure 6  Estimation of supply and demand of neurological care in regional Australia, 2020–2034, updated incidence and prevalence-based estimates of demand, preferential capacity allocation to review encounters.
encounters the deficits would be 269,821 in 2020 and 318,367 in 2034.

DISCUSSION
Here, we have undertaken the first assessment of the Australian neurologist workforce, demonstrating a marked shortfall in the ability of the present and projected workforce to meet patient demand for specialist outpatient neurology care. By multiple methodological approaches, we consistently demonstrated that the neurological workforce was insufficient to meet both demand for initial and follow-up outpatient care. These shortfalls and their projections exceeded critical levels in regional Australia. In the most plausible models, consistent subsidised increase in the number of neurologists mitigated but did not eliminate the deficits at either national or regional levels. These results indicate that unless more holistic efforts (incorporating increases to the workforce alongside improvements in systems of care) to improve neurology care in Australia are undertaken, the shortfalls in the availability of neurology care in Australia are likely to persist.

These results are in keeping with modelling in New Zealand. There, only a combination of increases to the number of neurologists and neurology support staff plus improved efficiency were sufficient to meet the demand of neurology care. Similarly, a study of the neurologist workforce in the USA found consistent deficits, which simulated interventions increasing neurologist numbers through greater recruitment and retention had only minor effects on. These studies alongside our own indicate that efforts to meet the demand of neurology care depends on but is not limited to increases in neurologist number. Ranta et al proposed more comprehensive changes to the neurology system of care, including increases in the number of neurologists, improved retention of existing neurologists, and increases in the number of neurology nurse specialists, as well as greater use of telehealth for regional/rural patients to access care, and enhancements to the communication interface between specialists and general practitioners, including electronic decision-support tools. The latter point would benefit from enhanced education modules for general practitioners, to support their diagnosis and management of some of the more common conditions, such as epilepsy, migraine and functional neurological disorders. Efforts to address the regional deficits may require focused interventions such as recruitment and retention incentives. We explored such retention in our simulated interventions but further exploration of these dynamics is needed.

Strengths and limitations
We have considered the Kurtzke-MacDonald metrics of neurology demand for neurology care, allowing comparability with previous work in our geographical region. In addition to this, we have improved on these metrics of demand of neurology care, conducting an updated review of the literature to estimate the prevalence and incidence of conditions likely requiring neurological care, as well as considering consult frequency and duration. However, this approach is limited in various respects. Our estimates are based on the estimated numbers of patients with such conditions, but not necessarily the numbers who are seeking care. Also, the frequencies and durations of clinic attendance were based on internal expert opinion by the ANZAN Workforce Committee rather than epidemiological data. For estimating durational load, though our estimates of demand were condition-specific, supply durations for initial and review encounters were estimated as the mean values expected for the current epidemiology of neurological conditions.

Our assessments of the distribution of patients with neurological conditions in regional Australia are proportional estimates based on Census data from the Australian Bureau of Statistics. Our projections regarding potential interventions to add neurologists in regional Australia may be optimistic in presumed longevity. Nonetheless, even with this overestimation of projected capacity, there were still persistent deficits, suggesting that our estimates of deficits in capacity are likely underestimates.

Our estimates of neurologist number may overestimate the workforce capacity since they include trainees. While trainees are semiautonomous in clinical settings, their capacity to provide care relies on consultation with neurology specialists. Despite this potential overestimation, we still see deficits in the supply of neurology outpatient care, so our estimates of deficit may underestimate the reality.

This project did not stratify the supply-demand balance by specialty areas, nor did it explore the distribution of neurologists across the career stages and by sex. These questions would warrant dedicated models in the future.

The impacts of short-term/long-term leave, immigration/emigration and partial/complete retirement on the available workforce were only partially captured in our analyses. Further exploration of these phenomena would be useful.

CONCLUSIONS
We have shown that the current access to specialist neurology care in Australia is suboptimal, nationally and especially in regional Australia. The projected trends indicate that the gap between the supply and the demand of neurology care will further widen over the coming years. This gap can be mitigated by sustainable increases in neurological workforce, but this is likely insufficient alone. Thus, while efforts to expand the workforce should be pursued, including investment in the neurology training programme and subsidy of more neurology positions, especially in regional Australia, this should be undertaken in concert with other initiatives, including (1) improvements in the efficiency of referral and care pathways; (2) expansion of the neurology support workforce, including specialist neurology nurses, nurse practitioners
and administrative support staff and (3) improvements in the training of general practitioners to diagnose and manage uncomplicated and common neurological conditions, ideally supplemented by evidenced based electronic decision support aids. These initiatives taken together will better enable the available outpatient neurology services to meet the patient demand.

**Author affiliations**
1. CORe, Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia
2. Neuroepidemiology Unit, Melbourne School of Population & Global Health, The University of Melbourne, Carlton, VIC, Australia
3. Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia
4. Department of Mathematics Computing, and Engineering Technologies, Swinburne University of Technology, Hawthorn, Victoria, Australia
5. Neuroimmunology Centre, Department of Neurology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
6. Concord Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
7. Neurology North Shore, Auckland, New Zealand
8. Department of Neurology, Launceston General Hospital, Launceston, Tasmania, Australia
9. School of Medicine and Psychology, Australian National University, Canberra, Australian Capital Territory, Australia
10. Centre for Neuromuscular and Neurological Disorders, Perron Institute for Neurological and Translational Science, University of Western Australia, Nedlands, Western Australia, Australia
11. Neurology, Sunshine Coast University Hospital, Sunshine Coast, Queensland, Australia

**Correction notice**
This article has been corrected since it was first published. A statement has been added to acknowledge funding support from the Australian and New Zealand Association of Neurologists.

**Contributors**
SS-Y undertook all analyses aside from ODE and primary manuscript drafting. FF undertook ODE analyses. JB, NC, LPG, CL, MN, BT and TK were on the expert consultation committee and provided critical revision. LH undertook work on an earlier iteration of this project and provided critical revision. CM provided critical revision and expert guidance. TK acts as guarantor for this work, and accepts full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish.

**Funding**
The authors would like to acknowledge the kind support for the open access fees for this article by the Australian and New Zealand Association of Neurologists.

**Competing interests**
CM has received conference travel support and/or speaker fees from Merck, Novartis and Biogen. He has received research support from the National Health and Medical Research Council, Multiple Sclerosis Research Australia, The University of Melbourne, The Royal Melbourne Hospital Neuroscience Foundation, and Dementia Australia. MN: I have received honoraria and consultancy fees from Abcuro, Sanofi-Genezyme, Roche, Biogen and CSL-Behring/Tomas Kalincik has served on scientific advisory boards for Roche, Sanofi-Genzyme, Novartis, Merck and Biogen, steering committee for Brain Atrophy Initiative by Sanofi-Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Novartis, Biogen, Sanofi-Genzyme, Teva, BioCSL and Merck and received research support from Biogen. Other authors have no conflicts of interest to report.

**Patient consent for publication**
Not applicable.

**Ethics approval**
This study did not require ethical review as it was undertaken solely using publicly available information and does not involve or report any data from any individual persons.

**Provenance and peer review**
Not commissioned; externally peer reviewed.

**Data availability statement**
Data are available on reasonable request. All data underlying the analyses in this paper are available on relevant request.

**Supplemental material**
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access**
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iD**
Steve Simpson-Yap http://orcid.org/0000-0001-6521-3056

**REFERENCES**


**Supplemental material**
Underlying the analyses in this paper are available on reasonable request. All data underlying the analyses in this paper are available on relevant request.

**Correction notice**
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
Correction: Modelling accessibility of adult neurology care in Australia, 2020–2034


This article has been corrected since it was first published. The following funding statement has now been added: ‘The authors would like to acknowledge the kind support for the open access fees for this article by the Australian and New Zealand Association of Neurologists.’

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

*BMJ Neurol Open* 2023;5:e000407corr1. doi:10.1136/bmjno-2023-000407corr1